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SINCE the introduction of Imuran and prednisone in 1961, and despite the addi-
tion of other adjuncts such as antithymocyte 
globulin (ATG) or thoracic duct drainage and 
the recognition of the importance of DR typ-
ing and blood transfusion, the major limita-
tion to successful renal transplantation has 
been the lack of selective immunosuppression. 
Standard immunosuppression has yielded 
graft survival rates of 50%-65%, with a high 
price in infections and other morbidity due to 
the high steroid doses required. With the 
fortuitous discovery of the immunosuppres-
sant activity of cyclosporin-A,' its testing in 
experimental animals,2.3 and demonstration of 
its efficacy in human transplantationI4~T the 
possibility seems to exist of making a quantum 
leap in clinical transplantation. In March 
1981, a randomized prospective trial compar-
ing Imuran and prednisone with cyclosporin-
A and prednisone in patients undergoing pri-
mary cadaveric renal transplantation was 
begun. This article reports the early results of 
that trial as well as the more recent experience 
utilizing cyclosporin-A in high-risk patients 
undergoing both primary and repeat cadav-
cric transplantation. These early results con-
firm the potent immunosuppressive effect of 
cyclosporin-A, the safety in conjunction with 
low doses of steroid, and the problem of neph-
rotoxicity. 
RANDOMIZED STUDY 
All patients accepted for primary cadaver 
transplant were eligible for study. Informed 
consent was obtained. All patients had 
received at least 3 U of type-specific whole 
blood prior to transplant. Upon completion of 
final cross match between donor lymphocytes 
and recipient serum, patients were random-
ized by computer-generated cards drawn in 
sequence to receive either Imuran and predni-
sone or cyclosporin-A and prednisone immu-
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nosuppression. The Imuran group rece.ived 
azathioprine, 5 mg/kg, for the first 3 day~ 
posttransplant, then tapered to a maintenance 
dose of 2,5 mg/kg/day over the next 2 weeks, 
Methylprednisolone (I g) was given i.v. pre-
operatively. Prednisone was begun on the day 
after surgery at 2 mg/kg/day and tapered to a 
dose of 0.5 mg/kg/day over 3 weeks. Subse-
quently, the prednisone dose was tapered to 
0.25 mg/kg/day by I year. The Cyclosporin-
A-treated group received cyclosporin-A 17.5 
mg/kg 4-6 hr preoperatively by mouth. The 
same dose was given daily thereafter in two 
divided doses. After 1-2 months, the dose was 
reduced to 12-14 mg/kg/ day and subse-
quently to 3-10 mg/kg/day depending on the 
clinical course. Methylprednisolone (1 g) was 
given i.v. preoperatively. Prednisone was given 
on the first postoperative day (200 mg) and 
reduced by 40-mg decrements over 5 days to 
20 mg/day. This was subsequently reduced to 
10-15 mg/ day, depending on the clinical 
course. Figure I shows the comparison of 
steroid doses in the early postoperative period. 
All patients in the cyclosporin-A group con-
tinued to receive full doses of cyclosporin-A 
whether or not there was immediate graft 
function. Rejection was diagnosed on clinical 
grounds. Treatment in each group consisted of 
recycling prednisone and in most cases, 450 
rad graft radiation in 3 divided doses on 
alternative days. 
Twenty-one patients were randomized to 
the cyclosporin-A group and 20 to the Imuran 
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Fig. 1. Comparison steroid doses. 
group. Table 1 lists the characteristics of each 
group. One-year graft survival for the cyclos-
porin-A group is 91 %. One-year graft survival 
for the [muran group is 56%. (Fig. 2). Two 
patients lost their kidneys in the cyclosporin-A 
group----one due to accelerated rejection due 
to receiving an ABO incompatible kidney, a 
violation of the protocol, the other due to 
cessation of immunosuppression due to a 
bowel perforation. No other kidneys were lost. 
Nine patients lost kidneys in the Imuran 
group--all to rejection. There were no deaths 
in either group (Fig. 3). 
Table 1. Randomized Imuran Versus Cyclosporin Trial: 
First Cadaveric Transplantation 
Imuran Cyclosporin-A 
N umber of patients 20 21 
Age range 20-56 25-61 
Mean age 42.8 41.7 
Mean A and B 
antigen match 1.2 1.0 
Mean A and B 
antigen mismatch 2.6 2.7 
Number of diabetics 4 4 
Nephrotoxicity was a common sequela to 
the use of cyclosporin-A, as were tremor, hair 
growth, and gum hyperplasia, though these 
latter were seldom troublesome. Most adjust-
ments in cyclosporin-A dose were made on 
clinical evidence of toxicity and carried out on 
an out-patient basis. The I-year creatinine, 
cyclosporin-A, and steroid doses of the 
patients in the randomized trial are listed in 
Table 2. 
Thirty-eight total patients were trans-
planted with cyclosporin-A and low dose pred-
nisone in 1981 and 31 with the I muran proto-
col. Graft survival overall was 92% and 55%, 
respectively. A comparison of the infection 
rates between the two groups shows a rate 
twice as high for the [muran-treated patients, 
while most infections encountered in the 
cyclosporin-A group were less serious. (Table 
3). 
Because of the demonstrated superiority of 
the cyclosporin-A and low steroid regimen, 
randomization was stopped, and the cyclos-
porin-A/steroid schedule was used for all 
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Table 2. Mean Posttransplant Levels 
Cyclosporin-A 
Prednisone 
Creatinine 
3 Months 
10 mg/kg/day 
14 mg/day 
1.94 mg/dl 
1 Year 
6 mg/kg/day 
12 mg/day 
1.98 mg/dl 
patients undergoing cadaveric transplantation 
over the past 16 months, including a large 
number of high-risk patients. Included in 
these 133 patients were 65 patients over 40 
years of age, 22 with diabetes mellitus, 18 
with antibodies to greater than 70% of ran-
dom lymphocytes tested, and 40 undergoing 
second, third, or fourth transplant of whom 27 
lost their previous graft in less than I year 
(Table 4). Overall I-year graft survival is 83% 
(Fig. 4). Overall patient survival is 95%. 
Seven deaths have occurred-5 from acute 
myocardial infarction (3 in diabetics over age 
45), I from sepsis secondary to bowel perfora-
tion, and I from complications from sickle-cell 
disease. Eleven patients have lost grafts secon-
dary to rejection. Four of these were primary 
transplants; 7 were repeat transplant patients. 
One of these patients was noncompliant, hav-
ing a perfectly functioning kidney until stop-
ping immunosuppression. The characteristics 
of the remaining 10 patients show 7 with 
percent reactive antibodies (PRA) greater 
than 70% and 6 complete HLA mismatches 
(Table 5). 
Two malignancies have been seen in these 
patients. One was a bowel lymphoma that was 
resected; the other was a Kaposi's sarcoma 
that resolved spontaneously on reduced 
cyclosporin-A dose. Both patients are alive 
with functioning kidneys. 
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Table 4. Cyclosporin-A Patient Population (133) 
Primary nondiabetic 
Repeat transplant 
Diabetic 
Mean HLA match 
No. over 40 years of age 
No. with PRA 70% 
No. with positive crossmatch to non-
concurrent serum 
DISCUSSION 
71 
40 
22 
1.0 
66 
18 
5 
This study confirms the potential useful-
ness of cyclosporin-A and low dose steroid to 
enable a high rate of graft survival with a low 
cost in morbidity or mortality. The results are 
similar to those reported by others testing the 
drug using a similar protocol.s The most effi-
cacious dose schedule has yet to be worked 
out, though the basic tenets of management 
that have proven successful are: beginning the 
drug preoperatively and continuing regardless 
of early diuresis or not, rapid tapering of 
steroid early in postoperative period, tapering 
cyclosporin-A over a longer period depending 
on clinical manifestations of toxicity. The 
rational for this approach has been discussed 
elsewhere.9 The early concerns about high 
incidence of lymphoma have not been evident 
so far. lo Two patients in this series have devel-
oped tumors, neither of which have proven 
lethal. 
Infection rate is significantly lower in 
cyclosporin-A-treated patients. Other salu-
tary effects due to decreased steroid require-
ments such as fewer cataracts, improved sense 
of well being, decreased Cushinoid appear-
ance, and fewer bone problems are apparent 
Table 3. Infections in Cadaver Kidney Transplants 1981 
Imuran (32) 
Pneumocystis pneumonia 3 
Pneumococcal pneumonia 
Staph pneumonia 1 
Osteomyelitis 4 
Perinephric abcess 1 
Total 10(31%) 
3 Grafts lost 
Cyclosporin-A (66) 
Pneumocystis pneumonia 
CMV pneumonia 
Generalized CMV 
Febrile UTI 
PID 
Sinusitis 
Epididymitis 
Total 
o Grafts lost 
3 
1 
2 
10 (15%) 
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Table 5. Characteristics of Patients With 
Rejection (11) 
No. 0 antigen match 
No. PRA >70% 
No. noncompliant 
No. active CMV 
No. repeat transnlant 
No. positive cross match 
6 
7 
6 
to those treating these patients, but not yet 
quantitated. 
Aside from the problem of resolving precise 
dosage schedules and balancing nephrotoxici-
ty, two other areas of concern exist. One is the 
long-term safety and efficacy, which will be 
answered in time. The other is its use in 
high-responder patients, be this measured by 
level of preformed antibodies, time to failure 
of previous transplants, or simply retrospec-
tively by the emergence of accelerated rejec-
tion. Although in this series of five patients 
transplanted against a positive crossmatch to 
both T and B cells in nonconcurrent sera, only 
one lost their graft. Eighteen patients had 
preformed antibodies against greater than 
133 
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70% of tested lymphocytes in both peak and 
concurrent sera; 7 of these patients lost kid-
neys to rejection, a graft survival much less 
than the remainder of the group. Since this is 
the type of patient filling more and more 
transplant lists, it remains a significant prub-
lem if the 90% graft survival that is obtainabic 
in other patients with cyclosporin-A and ste-
roid is to be obtained in this high-responder 
group. 
SUMMARY 
Cyclosporin A and steroid was compared to 
Imuran and prednisone in a prospective, ran-
domized study of patients undergoing primary 
cadaver renal transplantation. Graft survival 
was superior in the cyclosporin-A-treated 
group, with 1-year kidney function of 92(/r.' and 
less infections. No kidneys were lost to rejec-
tion in this group. Further experience with a 
variety of high-risk patients have reinforced 
this early experience, showing few kidneys lost 
to rejection and low incidence of infectious 
complications using cyclosporin-A and low 
dose steroid combination. 
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